Myelofibrosis drug approved in EU
28 August 2012 Business
Jakavi (ruxolitinib) tablets are for the treatment of myelofibrosis, a rare disease affecting the bone marrow
Gilead buys YM for $510m
20 December 2012
US pharma company Gilead is to buy YM BioSciences, a drug discovery firm based in Ontario, Canada, for $510 million (£310 million).
The lead drug candidate at YM is CYT387, a selective inhibitor of the Janus kinase (JAK) enzymes, which are thought to be involved in several of disorders, including myeloproliferative diseases, inflammatory disorders and certain types of cancer.
Gilead is planning a Phase III trial of CYT387 against myelofibrosis in the second half of 2013.
YM gained CYT387 when it bought Australian biotech Cytopia in 2009.
Most Read
Growing a microgarden
17 May 2013 Research
Barium carbonate crystals have been coaxed to form nano-flowers by controlling their chemical environment
Sugar solution to toxic gold recovery
15 May 2013 Research
The environmental legacy of salvaging gold from electronic waste can be dramatically cut using corn starch instead of cyanide
Most Commented
DCD in New Zealand milk
31 January 2013 Business
Dicyandiamide poses no food risk but fertiliser companies have suspended sales
3D printer churns out bionic ear
17 May 2013 Research
Seamless integration of electronics and tissue could be used with other artificial implants and synthetic organs